Partnership to speed up cell therapy delivery


Autolomous and BioCentriq have collaborated to digitise and accelerate process development and manufacturing activities for cell therapy.

Autolomous’ software platform is designed to materially affect the cell and gene therapy sector. BioCentriq will leverage the autoloMATE platform to streamline its process development operations and enhance client experience.

This partnership aims to ultimately accelerate batch delivery, ensuring patients have faster access to cell therapies.

David Smith, Vice President of Development at BioCentriq, said: “By streamlining data exchange throughout the development and manufacturing processes, we will be able to enhance operational efficiency and flexibility, de-risk timelines and ultimately deliver life-changing therapies to patients more quickly.”

Alexander Seyf, CEO and Co-founder of Autolomous, said: “The distinct capabilities of our platform are meticulously engineered to navigate and surmount the intricacies of cell and gene therapy development and production. Through our partnership, we are poised to accelerate towards a future where life-saving therapies are within reach of every patient in need, marking a significant leap forward in healthcare innovation.”

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free